Marcin Hołota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marcin Hołota has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Sylwia Michlewska
Laboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland
3 shared publications - Maksim Ionov
Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland
2 shared publications Maria Bryszewska
University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, Pomorska 141/143, Lodz 90-236, Poland
2 shared publicationsPaula Ortega
Universidad de Alcalá, Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Spain; Instituto Ramon y Cajal de Investigacion Sanitaria, IRYCIS, Colmenar Viejo Road, Km 9, 100, 28034 Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
2 shared publicationsAngela Dziedzic
University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biochemistry. Pomorska 141/143, Lodz 90-236, Poland
1 shared publicationCezary Watala
Department of Haemostatic Disorders, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka st. 6/8, 92-215 Lodz, Poland
1 shared publication
Latest Publications
- 6 July 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 701, 127145
Copper metallodendrimers effectively deliver proapoptotic siRNA to human liver carcinoma HepG2 cells
- 6 July 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 701, 127145
Copper metallodendrimers effectively deliver proapoptotic siRNA to human liver carcinoma HepG2 cells
- Open Access
- 29 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2108
Crossing Barriers: PEGylated Gold Nanoparticles as Promising Delivery Vehicles for siRNA Delivery in Alzheimer’s Disease
Background: The proportion of people suffering from neurodegenerative conditions, such as Alzheimer’s disease (AD), is increasing in the population year on year. Despite the constant effort of researchers, these conditions remain incurable and can only be managed by alleviation or delaying of symptoms. The lack of suitable treatment is caused by constricted access to the brain, limited by the brain-blood barrier. The aim of this work was to investigate two pegylated gold nanoparticles as potential carriers of therapeutic siRNA and their impact on the cellular functions of Human Brain Endothelial Cells. Methods and Results: Nanoparticles AuNP14a and AuNP14b complexed with siRNA were internalized by HBEC-5i cells and located in the cytoplasm. The genotoxicity assay proved that the nucleus was not affected and complexed nanoparticles did not cause DNA damage. The reactive oxygen species formation and mitochondrial membrane potential changes were measured and showed an adaptive response of cells after compound administration. Results obtained in a cytotoxicity assay conducted on astrocytes and pericytes, which are components of the blood–brain barrier, confirmed the biosafety of tested nanoparticles. Conclusions: In summary, it was shown that AuNP14a and AuNP14b are promising candidates as nanocarriers for therapeutic nucleic acids through biological barriers.
- 29 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2108
Open AccessCrossing Barriers: PEGylated Gold Nanoparticles as Promising Delivery Vehicles for siRNA Delivery in Alzheimer’s Disease
Background: The proportion of people suffering from neurodegenerative conditions, such as Alzheimer’s disease (AD), is increasing in the population year on year. Despite the constant effort of researchers, these conditions remain incurable and can only be managed by alleviation or delaying of symptoms. The lack of suitable treatment is caused by constricted access to the brain, limited by the brain-blood barrier. The aim of this work was to investigate two pegylated gold nanoparticles as potential carriers of therapeutic siRNA and their impact on the cellular functions of Human Brain Endothelial Cells. Methods and Results: Nanoparticles AuNP14a and AuNP14b complexed with siRNA were internalized by HBEC-5i cells and located in the cytoplasm. The genotoxicity assay proved that the nucleus was not affected and complexed nanoparticles did not cause DNA damage. The reactive oxygen species formation and mitochondrial membrane potential changes were measured and showed an adaptive response of cells after compound administration. Results obtained in a cytotoxicity assay conducted on astrocytes and pericytes, which are components of the blood–brain barrier, confirmed the biosafety of tested nanoparticles. Conclusions: In summary, it was shown that AuNP14a and AuNP14b are promising candidates as nanocarriers for therapeutic nucleic acids through biological barriers.
- Open Access
- 18 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6894
Nature-Inspired Strategies in Cancer Management: The Potential of Plant Extracts in Modulating Tumour Biology
Cancer is a serious group of diseases that is a huge problem on a global scale and is the second most common cause of death. Commonly used therapies do not always lead to the complete elimination of diseased cells or tissues and are also burdened with side effects that reduce the quality of life of patients. Due to these difficulties, new therapeutic approaches are still being sought. In recent years, there has been a return to interest in natural methods of treating various diseases, among which phytochemicals are particularly interesting. This article reviews plant extracts with anticancer properties with different mechanisms of action (proapoptotic, antiproliferative, antiangiogenic, immunomodulatory). In addition, plant extracts that reduce the side effects of chemotherapy and the limitations and prospects for the use of plant extracts in anticancer therapy are described. Our goal was to create an up-to-date information base that would encourage scientists to intensify research into supplementing targeted anticancer therapies with additional protective and preventive measures, in which natural mixtures of phytochemicals (plant extracts) are effective allies. At the same time, we encourage discussion on the limitations of their use in light of the orthodox principles of classical medicine and pharmacy (issues of safety, quality, drug purity, and dose precision), which are a priori correct but have not yet led to the elimination of cancer from the group of incurable diseases.
- 18 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6894
Open AccessNature-Inspired Strategies in Cancer Management: The Potential of Plant Extracts in Modulating Tumour Biology
Cancer is a serious group of diseases that is a huge problem on a global scale and is the second most common cause of death. Commonly used therapies do not always lead to the complete elimination of diseased cells or tissues and are also burdened with side effects that reduce the quality of life of patients. Due to these difficulties, new therapeutic approaches are still being sought. In recent years, there has been a return to interest in natural methods of treating various diseases, among which phytochemicals are particularly interesting. This article reviews plant extracts with anticancer properties with different mechanisms of action (proapoptotic, antiproliferative, antiangiogenic, immunomodulatory). In addition, plant extracts that reduce the side effects of chemotherapy and the limitations and prospects for the use of plant extracts in anticancer therapy are described. Our goal was to create an up-to-date information base that would encourage scientists to intensify research into supplementing targeted anticancer therapies with additional protective and preventive measures, in which natural mixtures of phytochemicals (plant extracts) are effective allies. At the same time, we encourage discussion on the limitations of their use in light of the orthodox principles of classical medicine and pharmacy (issues of safety, quality, drug purity, and dose precision), which are a priori correct but have not yet led to the elimination of cancer from the group of incurable diseases.
- 28 February 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 636, 122784
Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study
- 28 February 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 636, 122784
Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study